3,4-Dimethoxy-N,N-dimethylbenzeneethanamine Hydrochloride
CAS: 51012-67-0
Ref. TR-D476830
| 50mg | 245.00 € | ||
| 250mg | 919.00 € | ||
| 500mg | 1,627.00 € |
Estimated delivery in United States, on Tuesday 14 Jan 2025
Product Information
Name:
3,4-Dimethoxy-N,N-dimethylbenzeneethanamine Hydrochloride
Controlled Product
Synonyms:
- Verapamil Imp. C (EP)
- 2-(3,4-Dimethoxyphenyl)-N,N-dimethylethan-amine Hydrochloride
- Verapamil Hydrochloride Imp. C (EP) as Hydrochloride
- Verapamil Hydrochloride Impurity C as Hydrochloride
- Verapamil Impurity C as Hydrochloride,2-(3,4-Dimethoxyphenyl)-N,N-dimethylethanamine Hydrochloride
- Verapamil Hydrochloride Imp. C (EP)
Description:
Impurity Verapamil EP Impurity C HCl
Applications 3,4-Dimethoxy-N,N-dimethylbenzeneethanamine Hydrochloride (Verapamil EP Impurity C HCl) is an impurity of Verapamil (V125000), a calcium channel blocker, adrenergic antagonist (1). Antihypertensive; antianginal; antiarrhythmic (2) (class IV).
References 1. Atlas, D. et al.: Proc Natl Acad Sci U S A. 1981 Feb;78(2):1237-41.2. Yang, W. et al.: Cell Physiol Biochem. 2017 Apr 17;41(5):2104-2116
Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
TRC
Long term storage:
Notes:
Chemical properties
Molecular weight:
245.75
Formula:
C12H19NO2·ClH
Color/Form:
Neat
InChI:
InChI=1S/C12H19NO2.ClH/c1-13(2)8-7-10-5-6-11(14-3)12(9-10)15-4;/h5-6,9H,7-8H2,1-4H3;1H
InChI key:
InChIKey=ISRHVDOTIXGXOP-UHFFFAOYSA-N
SMILES:
CCOC(=O)N1CCC(Oc2ccc(C(Cl)c3ccccn3)cc2)CC1
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: TR-D476830 3,4-Dimethoxy-N,N-dimethylbenzeneethanamine Hydrochloride
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
